US · HCM · DRUG MANUFACTURERS - SPECIALTY & GENERIC
HUTCHMED (China) Limited (HCM) intrinsic value and stock valuation
$13.22as of 2026-11-21 · Mkt cap 2.02B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
HUTCHMED (China) Limited DCF and intrinsic value
InvestorsCraft values HCM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HCM’s statements →
HUTCHMED (China) Limited Graham Number
Graham Number: $20.92d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Kiniksa Pharmaceuticals International, plc (KNSA) $93.90
- Scholar Rock Holding Corporation (SRRK) $48.13
- Adaptive Biotechnologies Corporation (ADPT) $27.93
- IDEAYA Biosciences, Inc. (IDYA) $25.56
- Supernus Pharmaceuticals, Inc. (SUPN) $28.61
- Mineralys Therapeutics, Inc. (MLYS) $13.66
- Bausch Health Companies Inc. (BHC) $8.22
- Perrigo Company plc (PRGO) $15.94
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $550M | $630.2M | $838M | $426.4M | $356.1M |
| Operating income | -$-54.73M | -$-43.7M | $18.4M | -$-409.77M | -$-328.32M |
| Net income | $458.1M | $37.7M | $100.8M | -$-360.83M | -$-194.65M |
| EPSd | $2.62M | $216.1K | $579.7K | -$-2.13M | -$-1.23M |
| Operating cash flow | -$-64.66M | $500K | $219.3M | -$-268.6M | -$-204.22M |
| Capital expenditure | -$-24.15M | -$-17.93M | -$-32.61M | -$-36.66M | -$-16.76M |
| Free cash flow | -$-88.81M | -$-17.44M | $186.7M | -$-305.26M | -$-220.98M |
| Total assets | $1.75B | $1.27B | $1.28B | $1.03B | $1.37B |
| Total debt | $97.9M | $89.8M | $86.1M | $27M | $39M |
| Net debt | $26.6M | -$-64.14M | -$-197.46M | -$-286.27M | -$-338.56M |
| Total equity | $1.25B | $771.9M | $743.4M | $636.9M | $1.04B |
| Cash and short-term investments | $1.37B | $836.1M | $886.3M | $631M | $1.01B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $550M | $630.2M | $838M | $426.4M | $356.1M |
| Cost of revenue | $337.2M | $347.6M | $384.5M | $311.1M | $258.2M |
| Gross profit | $212.7M | $282.6M | $453.6M | $115.3M | $97.9M |
| Research and development expenses | $164.2M | $213.4M | $303.1M | $267.6M | $207.5M |
| Selling, general and administrative expenses | $103.3M | $112.9M | $133.2M | $136.1M | $127.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $119.3M | $91.6M |
| Operating expenses | $267.5M | $326.3M | $436.2M | $523M | $426.2M |
| Cost and expenses | $604.7M | $673.9M | $819.6M | $834.1M | $684.5M |
| Interest income | $50M | $40.1M | $36.2M | $9.6M | $2.08M |
| Interest expense | $2.87M | $2.87M | $760K | $650K | $590K |
| Depreciation and amortization | $13.3M | $12.3M | $8.21M | $8.66M | $7.19M |
| Ebitda | -$-41.38M | -$-31.36M | $26.6M | -$-401.11M | -$-207.96M |
| Operating income | -$-54.73M | -$-43.7M | $18.4M | -$-409.77M | -$-328.32M |
| Total other income/expenses, net | $577.5M | $89.1M | $87.2M | $51.5M | $173.2M |
| Income before tax | $522.7M | $45.4M | $105.6M | -$-360.24M | -$-155.33M |
| Income tax expense | $63.8M | $7.19M | $4.51M | -$-280K | $11.9M |
| Net income | $458.1M | $37.7M | $100.8M | -$-360.83M | -$-194.65M |
| Weighted average shares outstanding | $171.7M | $171.1M | $169.9M | $169.4M | $158.5M |
| Weighted average diluted shares outstanding | $174.6M | $174.6M | $173.8M | $169.4M | $158.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.37B | $836.1M | $886.3M | $631M | $1.01B |
| Net receivables | $147.8M | $167.7M | $150.5M | $126.7M | $147.7M |
| Inventory | $41.1M | $50.4M | $50.3M | $56.7M | $35.8M |
| Total current assets | $1.57B | $1.07B | $1.1B | $839.9M | $1.21B |
| Property, plant and equipment, net | $97.7M | $97M | $104.4M | $84.7M | $66.3M |
| Goodwill and intangible assets | $12.1M | $2.99M | $3.08M | $3.22M | $3.54M |
| Long-term investments | $52.3M | $0.00 | $48.4M | $73.8M | -$-557.68M |
| Total non-current assets | $185.8M | $207.6M | $182.9M | $189.6M | $160.6M |
| Total assets | $1.75B | $1.27B | $1.28B | $1.03B | $1.37B |
| Accounts payable | $45.5M | $42.5M | $36.3M | $71.1M | $41.2M |
| Short-term debt | $27.9M | $26.3M | $35.1M | $3.71M | $31.8M |
| Deferred revenue | $31.4M | $0.00 | $57.6M | $13.4M | $15.6M |
| Total current liabilities | $315.8M | $376.6M | $403M | $353.9M | $311.7M |
| Long-term debt | $70M | $63.5M | $51.1M | $23.3M | $7.16M |
| Deferred revenue, non-current | $20.1M | $48.4M | $69.5M | $190K | -$-2.77M |
| Total non-current liabilities | $186.1M | $125.8M | $133.4M | $38.7M | $21.5M |
| Capital lease obligations | $4.73M | $7.01M | $6.79M | $5.2M | $12.1M |
| Total liabilities | $501.8M | $502.3M | $536.4M | $392.6M | $333.2M |
| Common stock | $87.2M | $87.2M | $87.1M | $86.5M | $86.5M |
| Retained earnings | -$-378.64M | -$-833.17M | -$-870.87M | -$-971.48M | -$-610.33M |
| Accumulated other comprehensive income (loss) | -$-4.53M | $0.00 | -$-8.16M | -$-1.9M | $5.57M |
| Total equity | $1.25B | $771.9M | $743.4M | $636.9M | $1.04B |
| Total investments | $1.35B | $682.2M | $651.2M | $391.5M | $76.5M |
| Total debt | $97.9M | $89.8M | $86.1M | $27M | $39M |
| Net debt | $26.6M | -$-64.14M | -$-197.46M | -$-286.27M | -$-338.56M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $457.7M | $37.7M | $100.8M | -$-360.39M | -$-167.04M |
| Depreciation and amortization | $13.3M | $12.3M | $8.21M | $8.66M | $7.19M |
| Stock-based compensation | $15.3M | $21.6M | $36.6M | $30.6M | $42M |
| Change in working capital | -$-60.86M | -$-62.17M | $71.2M | $58.7M | $32.5M |
| Accounts receivable | $24.2M | -$-41.57M | -$-13.05M | -$-2.38M | -$-41.39M |
| Inventory | $9.54M | -$-770K | $4.13M | -$-21.21M | -$-16M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-64.66M | $500K | $219.3M | -$-268.6M | -$-204.22M |
| Investments in property, plant and equipment | -$-14.15M | -$-17.93M | -$-32.61M | -$-36.66M | -$-16.76M |
| Acquisitions, net | $608.5M | $0.00 | -$-2.99M | $320K | $0.00 |
| Net cash used for investing activities | -$-29.41M | -$-96.06M | -$-291.14M | $296.6M | -$-306.32M |
| Common stock issued | $1.58M | $790K | $5.09M | $170K | $717.3M |
| Common stock repurchased | $0.00 | -$-36.06M | -$-9.07M | -$-48.08M | -$-27.31M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $7.84M | -$-30.67M | $48.7M | -$-82.76M | $650M |
| Net change in cash | -$-82.63M | -$-129.63M | -$-29.69M | -$-64.26M | $141.9M |
| Cash at end of period | $71.3M | $154M | $283.6M | $313.3M | $377.5M |
| Operating cash flow | -$-64.66M | $500K | $219.3M | -$-268.6M | -$-204.22M |
| Capital expenditure | -$-24.15M | -$-17.93M | -$-32.61M | -$-36.66M | -$-16.76M |
| Free cash flow | -$-88.81M | -$-17.44M | $186.7M | -$-305.26M | -$-220.98M |
Line items
Line items
Line items
About HUTCHMED (China) Limited
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
- CEO
- Chig Fung Cheng
- Employees
- 1.8K
- Beta
- 0.43
Explore
Frequently asked questions
What is the intrinsic value of HUTCHMED (China) Limited (HCM)?
InvestorsCraft does not currently publish an intrinsic value for HCM. How the IC value is calculated.
Is HCM undervalued?
InvestorsCraft does not publish an undervaluation signal for HCM at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.